ArticleGut2023

Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.

Chao-Yang Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.